Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer.

Cancer Prevention Research
Yian WangM You

Abstract

In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.

References

Sep 2, 1994·Journal of Medicinal Chemistry·M F BoehmR A Heyman
Dec 15, 1995·Cell·D J Mangelsdorf, R M Evans
Nov 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J HofmannK Havemann
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V A MillerR P Warrell
Feb 26, 1998·American Journal of Respiratory Cell and Molecular Biology·V GouyerE Brambilla
Sep 28, 1999·Oncogene·D A Tuveson, T Jacks
Jan 6, 2000·The Tohoku Journal of Experimental Medicine·S KobayashiS Fujimura
Aug 10, 2000·Journal of Cancer Research and Clinical Oncology·K JunkerK M Müller
Nov 4, 2000·Expert Opinion on Investigational Drugs·F P Worden, G P Kalemkerian
Sep 3, 2002·Cancer Cell·Charles J Sherr, Frank McCormick
Feb 8, 2005·Clinical Lung Cancer·Konstantin H DragnevEthan Dmitrovsky
Mar 17, 2005·Genes & Development·Ralph Meuwissen, Anton Berns
Dec 7, 2005·International Journal of Cancer. Journal International Du Cancer·Michael A PereiraRonald A Lubet
Dec 19, 2006·Journal of Neuroimmunology·Cindy X Zhang-Gandhi, Paul D Drew
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen LibyMichael B Sporn

❮ Previous
Next ❯

Citations

May 6, 2014·Critical Reviews in Oncology/hematology·Molin LiChuangang Li
Nov 1, 2015·Nucleic Acids Research·Pora KimZhongming Zhao
Nov 22, 2012·Expert Opinion on Investigational Drugs·Konstantine DragnevRonald Lubet
Mar 13, 2016·Seminars in Oncology·Iván P UrayPowel H Brown
Sep 18, 2012·Pharmacology & Therapeutics·Shannon HealyJames R Davie
Jul 27, 2010·Advanced Drug Delivery Reviews·Nathan Bushue, Yu-Jui Yvonne Wan
Jan 23, 2016·The Journal of Endocrinology·Kerryn M TaylorPaula Sommer
Mar 10, 2018·Expert Review of Anticancer Therapy·Danyang ShenLiqun Xia
Aug 8, 2020·International Journal of Molecular Sciences·Sherri L SurmanJulia L Hurwitz
Jan 5, 2019·Cancer Prevention Research·Arthur R GalbraithFrank G Ondrey
Mar 10, 2012·Cancer Prevention Research·Qi ZhangMing You

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis